CellSource Co

CellSource Co Change in Working Capital

The Change in Working Capital of CellSource Co (4880.T) as of Oct 27, 2026 is 19.18 M JPY. In the previous year, Change in Working Capital was 333.50 M JPY — a change of -94.25% (lower).

Change in Working Capital

19.18 MJPY

YoY

-94.25%

Last updated:

Change in Working Capital of CellSource Co is 2025 19.18 M JPY. Change in Working Capital of CellSource Co was 2024 333.50 M JPY. It decreases by -94.25% lower compared to the previous year.

The CellSource Co Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
-16.05 M JPY
Jan 1, 2019
-36.24 M JPY
Jan 1, 2020
-76.86 M JPY
Jan 1, 2021
-36.89 M JPY
Jan 1, 2022
-344.09 M JPY
Jan 1, 2023
195.22 M JPY
Jan 1, 2024
333.50 M JPY
Jan 1, 2025
19.18 M JPY
The CellSource Co Change in Working Capital history
YEARChange in Working CapitalYoY
19.18 MJPY-94.25%
333.50 MJPY+70.83%
195.22 MJPY-156.73%
-344.09 MJPY+832.86%
-36.89 MJPY-52.01%
-76.86 MJPY+112.09%
-36.24 MJPY+125.75%
-16.05 MJPY-78.05%
-73.14 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Change in Working Capital of CellSource Co is 19.18 M JPY in 2025.

Change in Working Capital of CellSource Co changed from 333.50 M JPY to 19.18 M JPY, representing a -94.25% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — CellSource Co

All Key Metrics — CellSource Co